Form 4 for NVCR NovoCure Ltd
Accepted 2024-06-06 00:00:00 ET · period of report 2024-06-04 · accession 0001562180-24-004761 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-06 | 2024-06-04 | NVCR | VERNON W ANTHONY | Dir | S - Sale | $23.89 | -964 | 164.8K | -0.6% | -$23.0K |
| D | 2024-06-06 | 2024-06-05 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +4,053 | 169.8K | +2% | $0 |
| D | 2024-06-06 | 2024-06-05 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +6,229 | 6,229 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-06-04 | S | D | 964 | $23.89 | 164,833 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price. |
| 2 | Common | Restricted Stock Units | 2024-06-05 | A | A | 4,053 | $0.00 | 169,850 | D | — | — | (F2) These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-06-05 | A | A | 6,229 | $0.00 | 6,229 | D | $23.13 · — to 2034-06-04 | 6,229 Ordinary Shares | (F3) Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. |